

Drug and Therapeutics Committee – Minutes

Date / Time	December 8 th 2022
Venue	WebEx
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, Formulary HUTH
Quorate: Yes / No	Yes

Attendance	Prof A Morice, Chair, Professor of Respiratory Medicine
	Mr K McCorry, Medicines Optimisation Pharmacist, NECS
	Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH
	Mr P O'Brien, Deputy Chief Pharmacist, HUTH
	Dr S Raise, GP Prescribing Lead, East Riding
	Prof M Lind, Vice Chair, Professor of Oncology, HUTH
	Dr O Ogunbambi, Consultant Rheumatologist, HUTH
	Dr A Samson, Consultant Infectious Diseases, HUTH

Apologies	Ms J Goode, Chief Pharmacist, HUTH
	Luke Storr – Senior Pharmacy Technician, Formulary HUTH
	Dr H Klonin, Consultant Paediatrician, HUTH

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.11.01	Apologies	As Above.					
2022.11.02	Declarations of Interest	None					
2022.11.03	Minutes of the previous meeting	Accepted as true record					
2022.11.05	Action Tracker	<p>Hydroxychloroquine in RA New action: JM to discuss with relevant business managers Update: August 2022 – to escalate via PE&CE Update: September 2022 – escalated via PE&CE Update: November 2022 – going to December PE&CE</p> <p>ARIA forms – Zoledronic acid JM to write trust guidance in conjunction with DME pharmacy team</p> <p>NICE Guidance JM to meet with neurology about TA758 (Solriamfetol) New action: to check back of formulary and update</p> <p>Clinical guidelines – Biologics and small molecules for IBD JM to meet with SS (with surgical team pharmacists) to work on updated guidance and discuss audit- JM and SS not met (date in diary) JG to ensure new pharmacy service to IMIC is set up- JG not present to give update New action: Add guidance to agenda when updated New action Sept 2022: Present audit of usetikinumab</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>JM to meet with Prof Sebastian and finalise guideline</p> <p>JG to update next time</p> <p>Ongoing</p>	<p>JM to speak to Matthew Heppel</p> <p>JM/SS to meet</p>	<p>JM</p> <p>JM</p> <p>JG</p>	<p>1/23</p> <p>1/23</p> <p>1/23</p>	<p>12/22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		Chairs approvals AM to write Dr Taylor about application for IV doxycycline for seroma Supply problems JM to contact immunology about replacement for Oralvac dog dander	Action complete Action complete				12/23 12/23
2022.11.06	Supply Issues	Remdesivir IV- new guidance to be issued Cicloserine- 3 month shortage Aztreonam- ABX team aware Diamox (acetazolamide IV)- 4 month supply issue- unlicensed item incoming Chlordiazepoxide- Usage restricted and guidance provided Penicillin V- stock incoming slowly	No action required				12/23
2022.11.07	New Product Requests	New Product Requests a) Tenecteplase (Dr Esisi) Unlicensed indication for tenecteplase for thrombolysis with thromectomy in large vessel infarcts. Recommended in European stroke guidance however, product is marked up with dosages for the licensed MI dose. The licensed dose is twice the dose required for stroke thrombolysis so risk of double dosing. To refer to SMPC to discuss risk management. b) Upadacitinib (Prof Sebastian) Application for use in UC and CD. Licensed for use in UC and NICE due Jan 2023 but not licensed in CD. Trials are ongoing in CD but phase 3 not yet published. A free of charge scheme is available for UC and Prof Sebastian is trying to get a compassionate use scheme for CD. Approve for chairs approvals only. ARIA FORMS c) Carboplatin & Paclitaxel + Pembrolizumab - EC & Pembrolizumab [Neoadjuvant] for TNBC Dietetic product request c) ProSource TF ENFit	a) Approved subject to approval with SMPC b) UC-Chairs approval until Jan TA Chairs approval for Crohn's c) Approved d) Approved	JM to discuss with Simon Gaines AM to write to applicants LS to update formulary	JM AM LS	1/23 1/23 1/23	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		This is a line extension with a product we already use but in an ENFit syringe rather than sachet, which is a safety feature and saves nursing time.					
2022.11.08	NICE guidance	NICE Guidance November 22 <ul style="list-style-type: none">• TA838 Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)• NG227 Advocacy services for adults with health and social care needs• TA839 Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)• TA840 Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)• TA841 Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)• TA842 Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)• NG37 Fractures (complex): assessment and management• NG228 Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management• TA843 Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)• TA844 Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)• TA845 Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)	Terminated appraisal Nothing for HUTH Terminated appraisal Terminated appraisal Terminated appraisal Nothing for D&TC Nothing for D&TC Terminated appraisal Terminated appraisal Terminated appraisal Terminated appraisal				

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> TA846 Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) TA847 Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) 	Terminated appraisal				
2022.11.09	MHRA Drug safety update	<ul style="list-style-type: none"> November 2022 	Noted				
2022.11.10	Minutes of the Safe Medication Practice Committee	<ul style="list-style-type: none"> September 2022 		No action required			
2022.11.11	Minutes from the Hull and East Riding Prescribing Committee	a) October 2022	Complete	No action required			
2022.11.12	Regional Medicines Optimisation Committee	Nil this month	Noted	No action required			
2022.11.13	Clinical guidelines	Nil this month		No action required			
2022.11.14	Correspondence received	<ul style="list-style-type: none"> Growth Hormone- Dr Mathew 					
2022.11.15	Chairs Approvals	<ul style="list-style-type: none"> Cefiderocol (Dr Ivan) Oral ephedrine (Dr Mehta) 					
2022.11.17	Issues to escalate to PE&CE	Nil this month					
2022.11.18	Any Other Business	Nil this month					
2022.11.19	Date and Time of Next Meeting	January 12 th 2023 8:15 am via Teams					

